PB 147 of 2025
National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025
I, Rebecca Richardson, Assistant Secretary, Pricing and PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make the following determination.
Dated 27 November 2025
REBECCA RICHARDSON
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
(1) This instrument is the National Health (December 2025 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2025.
(2) This instrument may also be cited as PB 147 of 2025.
2 Commencement
This instrument commences on 1 December 2025.
3 Authority
This instrument is made under subsection 99ACB(6A) of the National Health Act 1953.
4 Definitions
Note: A number of expressions used in this instrument are defined in Part VII the Act.
In this instrument:
Act means the National Health Act 1953.
5 Brand of pharmaceutical item not subject to a price reduction
- I determine under paragraph 99ACB(6A)(a) of the Act that the agreed price of the brand of pharmaceutical item specified in item 1 in the table in Part 1 of Schedule 1 that comes into force on 1 December 2025 is to be equal to the approved ex‑manufacturer price, on the day before the determination day, of the existing brand of the existing item.
Schedule 1 Brands of pharmaceutical item not subject to a price reduction
Part 1
Column 1 | Column 2 | |||
Item | Brand of pharmaceutical item | |||
| Drug | Form | Manner of administration | Brand |
1 | Drospirenone
| Pack containing 24 tablets 4 mg and 4 inert tablets
| Oral | Lucinda |